Studies support targeted use of C-11 PET/CT in prostate cancer evaluation

May 24, 2012

C-11 choline PET/CT substantially improved sensitivity for lesion detection in the re-staging of patients with prostate cancer, according to a study presented May 23 at the annual meeting of the American Urological Association in Atlanta. However, its utility was limited in the initial staging of men with high-risk prostate cancer. R. Jeffery Karnes, MD, from the Mayo Clinic in Rochester, Minn., and colleagues presented three studies exploring potential applications of C-11 choline PET/CT in prostate cancer at the annual meeting.